109 related articles for article (PubMed ID: 16499663)
1. The invasive behaviour of prostatic cancer cells is suppressed by inhibitors of tyrosine kinase.
Skogseth H; Larsson E; Halgunset J
APMIS; 2006 Jan; 114(1):61-6. PubMed ID: 16499663
[TBL] [Abstract][Full Text] [Related]
2. Urokinase plasminogen activator receptor (uPAR) expression is reduced by tyrosine kinase inhibitors.
Skogseth H; Larsson E; Halgunset J
APMIS; 2006 Apr; 114(4):307-13. PubMed ID: 16689831
[TBL] [Abstract][Full Text] [Related]
3. Transcription levels of invasion-related genes in prostate cancer cells are modified by inhibitors of tyrosine kinase.
Skogseth H; Follestad T; Larsson E; Halgunset J
APMIS; 2006 May; 114(5):364-71. PubMed ID: 16725013
[TBL] [Abstract][Full Text] [Related]
4. Effect of hepatocyte growth factor on invasion of prostate cancer cell lines.
Fujiuchi Y; Nagakawa O; Murakami K; Fuse H; Saiki I
Oncol Rep; 2003; 10(4):1001-6. PubMed ID: 12792760
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase inhibitors alter adhesivity of prostatic cancer cells to extracellular matrix components.
Skogseth H; Holt RU; Larsson E; Halgunset J
APMIS; 2006 Mar; 114(3):225-33. PubMed ID: 16643189
[TBL] [Abstract][Full Text] [Related]
6. Osteoblasts modulate secretion of urokinase-type plasminogen activator (uPA) and matrix metalloproteinase-9 (MMP-9) in human prostate cancer cells promoting migration and matrigel invasion.
Festuccia C; Giunciuglio D; Guerra F; Villanova I; Angelucci A; Manduca P; Teti A; Albini A; Bologna M
Oncol Res; 1999; 11(1):17-31. PubMed ID: 10451028
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of tyrosine kinase inhibit the production of urokinase plasminogen activator in human prostatic cancer cells.
Skogseth H; Larsson E; Halgunset J
APMIS; 2005 May; 113(5):332-9. PubMed ID: 16011659
[TBL] [Abstract][Full Text] [Related]
8. Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK.
Hecht M; Heider U; Kaiser M; von Metzler I; Sterz J; Sezer O
Br J Haematol; 2007 Aug; 138(4):446-58. PubMed ID: 17593251
[TBL] [Abstract][Full Text] [Related]
9. Human thyroid carcinoma cell invasion is controlled by the low density lipoprotein receptor-related protein-mediated clearance of urokinase plasminogen activator.
Sid B; Dedieu S; Delorme N; Sartelet H; Rath GM; Bellon G; Martiny L
Int J Biochem Cell Biol; 2006; 38(10):1729-40. PubMed ID: 16807059
[TBL] [Abstract][Full Text] [Related]
10. Urokinase-mediated extracellular matrix degradation by human prostatic carcinoma cells and its inhibition by retinoic acid.
Webber MM; Waghray A
Clin Cancer Res; 1995 Jul; 1(7):755-61. PubMed ID: 9816042
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1.
Ramer R; Hinz B
J Natl Cancer Inst; 2008 Jan; 100(1):59-69. PubMed ID: 18159069
[TBL] [Abstract][Full Text] [Related]
12. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
13. Tetrahydrocurcumin inhibits HT1080 cell migration and invasion via downregulation of MMPs and uPA.
Yodkeeree S; Garbisa S; Limtrakul P
Acta Pharmacol Sin; 2008 Jul; 29(7):853-60. PubMed ID: 18565284
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
Festuccia C; Dolo V; Guerra F; Violini S; Muzi P; Pavan A; Bologna M
Clin Exp Metastasis; 1998 Aug; 16(6):513-28. PubMed ID: 9872599
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
16. The influence of CD44v3-v10 on adhesion, invasion and MMP-14 expression in prostate cancer cells.
Harrison GM; Davies G; Martin TA; Mason MD; Jiang WG
Oncol Rep; 2006 Jan; 15(1):199-206. PubMed ID: 16328056
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor effect of ascorbic acid, lysine, proline, arginine, and epigallocatechin gallate on prostate cancer cell lines PC-3, LNCaP, and DU145.
Roomi MW; Ivanov V; Kalinovsky T; Niedzwiecki A; Rath M
Res Commun Mol Pathol Pharmacol; 2004; 115-116():251-64. PubMed ID: 17564322
[TBL] [Abstract][Full Text] [Related]
18. Stimulation of human breast carcinoma cell invasiveness and urokinase plasminogen activator activity by glucose deprivation.
Belkacemi L; Lam E; Caldwell JD; Siemens DR; Graham CH
Exp Cell Res; 2006 Jun; 312(10):1685-92. PubMed ID: 16564525
[TBL] [Abstract][Full Text] [Related]
19. RRR-alpha-tocopheryl succinate inhibits human prostate cancer cell invasiveness.
Zhang M; Altuwaijri S; Yeh S
Oncogene; 2004 Apr; 23(17):3080-8. PubMed ID: 15048090
[TBL] [Abstract][Full Text] [Related]
20. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
